Treatment of osteolytic, osteoblastic & mixed bone metastases of solid tumors & osteolytic lesions of multiple myeloma in conjunction w/ standard antineoplastic therapy. Treatment of hypercalcemia of malignancy (HCM). Reduction of bone damage in patients w/ advanced malignancies involving bone.
Dosage/Direction for Use
IV infusion of no <15 min. Adult & elderlyBone metastases & osteolytic lesions; bone damage in patients w/ advanced malignancies involving bone 4 mg every 3-4 wk. Administer oral Ca supplement 500 mg & vit D 400 IU daily. HCM 4 mg.
Hypersensitivity to bisphosphonates. Pregnancy & lactation, hypocalcemia.
Severe renal impairment. Monitor serum Ca, phosphate, Mg & creatinine. Ensure adequate hydration. Avoid invasive dental procedures in patients w/ concomitant risk factors (eg, cancer, chemotherapy, corticosteroids, poor oral hygiene) due to risk of osteonecrosis of the jaw.
Anemia, headache, conjunctivitis, nausea, vomiting, anorexia, bone pain, myalgia, arthralgia, renal impairment, fever, flu-like syndrome, hypophosphatemia, increased blood creatinine & blood urea, hypocalcemia, osteonecrosis of the jaw.
Aminoglycosides, other potentially nephrotoxic drugs, thalidomide. Must not be mixed w/ Ca or other divalent cation-containing infusion soln eg, lactated Ringer's soln. Should be administered as a single IV soln & in a line separate from all other drugs.